FOR IMMEDIATE RELEASE December 4, 2025 HEADLINE PP-405 Gains Attention as a Novel Small-Molecule Therapy for Hair Loss Following Early Clinical Signals SUMMARY PP-405, an investigational topical small-molecule therapy for hair loss, is drawing interest after early clinical data suggested meaningful hair regrowth with a favorable safety profile. Dermatologists are watching closely as this new mechanism advances through clinical development for androgenetic alopecia. BACKGRO

FOR IMMEDIATE RELEASE December 4, 2025 HEADLINE New Phase III Data for Breezula® (Clascoterone) Shows Strong Hair-Count Gains and Robust Safety in Androgenetic Alopecia Trials SUMMARY Topical androgen receptor inhibitor Breezula® (clascoterone 5% solution) has met its co-primary endpoints in two Phase III trials, showing substantial improvements in scalp hair count over vehicle — raising hopes for a new non-systemic therapy for pattern hair loss. New York hair-loss special

FOR IMMEDIATE RELEASE December 2, 2025 Taipei, Taiwan HEADLINE New Taiwanese Mouse Study Identifies Fat-Cell Signaling Pathway That Triggers Hair Regrowth SUMMARY A newly released study from researchers at National Taiwan University (NTU) shows that topical application of specific fatty acids stimulated rapid and robust hair regrowth in hairless mice. New York dermatologist Dr. Dennis Porto notes that while the findings are compelling, translation to humans remains uncerta

FOR IMMEDIATE RELEASE HEADLINE Cemiplimab Continues to Show Strong Outcomes for Advanced Cutaneous Squamous Cell Carcinoma SUMMARY Cemiplimab, the first FDA-approved PD-1 inhibitor specifically indicated for advanced cutaneous squamous cell carcinoma (cSCC), continues to demonstrate high response rates and durable tumor control in ongoing clinical research. New York Mohs surgeon Dr. Dennis Porto highlights its importance as an option for patients with aggressive or unresectab

FOR IMMEDIATE RELEASE HEADLINE Medicus Microneedling-Based Therapy Enters Clinical Evaluation for Basal Cell Carcinoma SUMMARY A novel microneedling-based drug delivery platform is being investigated as a potential non-surgical treatment for basal cell carcinoma (BCC). New York Mohs surgeon Dr. Dennis Porto comments on the promise and limitations of this investigational approach as early trial data emerge. BACKGROUND: BASAL CELL CARCINOMA AND CURRENT TREATMENTS Basal cell car

FOR IMMEDIATE RELEASE HEADLINE PH-762: A Novel siRNA Immunotherapy Could Transform Skin Cancer Treatment, Says New York Dermatologist SUMMARY PH-762, an experimental small-interfering RNA (siRNA) therapy designed to silence the PD-1 gene, has shown promising early results in a Phase 1b clinical trial for cutaneous skin cancers. New York Mohs surgeon and dermatologist Dr. Dennis Porto comments on the potential of this non-surgical, gene-targeted approach to reshape skin canc

FOR IMMEDIATE RELEASE HEADLINE New Studies Indicate Elevated Skin Cancer Risk in Patients with Atopic Dermatitis — Dermatologists Urge Vigilance SUMMARY Recent large-scale analyses suggest that patients with atopic dermatitis (AD) face a modest but significant increase in risk for non-melanoma skin cancer compared with individuals without AD. New York Mohs surgeon and dermatologist Dr. Dennis Porto calls for more proactive skin cancer surveillance among eczema patients. BAC

FOR IMMEDIATE RELEASE HEADLINE New Research Links Alcohol Consumption to Melasma — Dermatologists Advise Patients to Consider Lifestyle Changes SUMMARY Recent studies suggest that alcohol intake may be a previously underrecognized trigger for melasma. New York dermatologist Dr. Dennis Porto emphasizes the importance of discussing alcohol as part of comprehensive melasma management. BACKGROUND: MELASMA — COMPLEX CAUSES AND CHRONIC BURDEN Melasma is a common pigmentary disor

FOR IMMEDIATE RELEASE HEADLINE Tralokinumab Shows Strong Clinical Benefit for Moderate-to-Severe Atopic Dermatitis SUMMARY Tralokinumab (marketed in the U.S. as Adbry) is an FDA-approved biologic therapy targeting interleukin-13 (IL-13) for moderate-to-severe atopic dermatitis. New York dermatologist Dr. Dennis Porto explains why this therapy may be especially helpful for patients whose eczema has been difficult to control. BACKGROUND: ATOPIC DERMATITIS AND ITS CHALLENGES Ato

FOR IMMEDIATE RELEASE HEADLINE INF904 Oral C5aR Inhibitor Offers a Potential Non-Surgical Treatment for Hidradenitis Suppurativa SUMMARY INF904, an oral small-molecule inhibitor targeting the C5a receptor (C5aR), has demonstrated promising early clinical results in reducing lesion burden and pain in patients with hidradenitis suppurativa (HS), offering a potential non-surgical alternative for this debilitating chronic skin disease, says New York dermatologist Dr. Dennis Porto

FOR IMMEDIATE RELEASE HEADLINE Opzelura Offers New Steroid-Free Option for Vitiligo and Eczema, Marking a Major Advancement in Dermatology SUMMARY Opzelura (ruxolitinib cream) is the first topical Janus kinase (JAK) inhibitor approved for both vitiligo and atopic dermatitis. New York dermatologist Dr. Dennis Porto highlights how this steroid-free therapy expands treatment choices for chronic inflammatory skin diseases. BACKGROUND: VITILIGO AND ECZEMA Vitiligo and eczema are t

FOR IMMEDIATE RELEASE HEADLINE Low-Dose Isotretinoin Gains Attention as an Emerging Off-Label Anti-Aging Therapy in Dermatology SUMMARY Low-dose isotretinoin, traditionally used to treat severe acne, is gaining interest as a potential off-label anti-aging therapy. New York dermatologist Dr. Dennis Porto highlights growing enthusiasm among patients and clinicians as studies continue to explore its benefits beyond acne. BACKGROUND: SKIN AGING AND TRADITIONAL RETINOID THERAPIES

FOR IMMEDIATE RELEASE HEADLINE Extended-Release Oral Minoxidil (VDPHL01) Shows Promise as New Treatment for Pattern Hair Loss, Announces New York Dermatologist SUMMARY VDPHL01, a novel extended-release oral minoxidil formulation, is advancing through late-stage clinical trials and may offer a more effective and better-tolerated option for patients with pattern hair loss, according to New York dermatologist Dr. Dennis Porto. BACKGROUND: PATTERN HAIR LOSS Pattern hair loss (and